Michael Blocker

Enhanced terminal room disinfection and acquisition and infection caused by multidrug-resistant organisms and Clostridium difficile (the Benefits of Enhanced Terminal Room Disinfection study): a cluster-randomised, multicentre, crossover study

Deverick J. Anderson, Luke F. Chen, David J. Weber et al. · The Lancet · 2017 · 338 citations · Full text

Antimicrobial Susceptibility, Health Sciences, Antibiotics +11

Effectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and Clostridium difficile: a secondary analysis of a multicentre cluster randomised controlled trial with crossover design (BETR Disinfection)

Deverick J. Anderson, Rebekah W. Moehring, David J. Weber et al. · The Lancet Infectious Diseases · 2018 · 125 citations

Antimicrobial Susceptibility, Health Sciences, Antibiotics +11

Clonal Relationships Among High‐Level Penicillin‐Resistant<i>Streptococcus pneumoniae</i>in the United States

Gary V. Doern, Angela B. Brueggemann, Michael Blocker et al. · Clinical Infectious Diseases · 1998 · 55 citations · Full text

Antimicrobial susceptibility of nasopharyngeal isolates of potential pathogens recovered from infants before antibiotic therapy

Howard Faden, Gary V. Doern, Judy Wolf et al. · The Pediatric Infectious Disease Journal · 1994 · 39 citations

Implementation Lessons Learned From the Benefits of Enhanced Terminal Room (BETR) Disinfection Study: Process and Perceptions of Enhanced Disinfection with Ultraviolet Disinfection Devices

Deverick J. Anderson, Lauren P. Knelson, Rebekah W. Moehring et al. · Infection Control and Hospital Epidemiology · 2018 · 37 citations · Full text